Dr. Watt’s research aims to identify novel markers of breast cancer risk and to understand the long-term risks of disease related to cancer treatment. The first area of investigation seeks to identify imaging features on mammogram and breast magnetic resonance imaging (MRI) that identify women with an increased risk of breast cancer. In particular, Dr. Watt is focused on a measure called background parenchymal enhancement (BPE), measured on MRI, which is a promising new marker of future breast cancer risk. He is now investigating whether BPE measured on contrast-enhanced mammogram, a more affordable modality than MRI, may also identify women with an increased risk of breast cancer. The second area of investigation concerns the health of survivors of pediatric and adult cancers. Previously, he worked with the WECARE Study collaborative team to show that the receipt of left-sided vs right-sided breast radiation therapy was associated with a more than 2-fold increased risk of subsequent coronary artery disease. Other work with the WECARE Study has identified genetic factors that increase the risk of radiation-associated second primary breast cancers after receiving radiation therapy for a first breast cancer. He recently received a Career Development Award from the Childhood Cancer Survivors Study to identify genetic factors that may increase the risk of second primary cancers among survivors of pediatric cancers.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Gordon P. Watt discloses the following relationships and financial interests:
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.